Highest-materiality recent filing
MetLife pre-announces Q2 2026 variable investment income of ~$220-270M, well below annual guidance
Estimates Q2 2026 variable investment income at $220M-$270M pre-tax, including private equity, real estate, and prepayment fees.
MetLife Q1 2026 net income rises 30% to $1.1B, adjusted EPS up 23% to $2.42
Adjusted earnings up 18% to $1.6B driven by higher variable investment income and volume growth.
MetLife issues $1B of 5.850% subordinated debentures due 2056
Issued $1B aggregate principal of 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056.
FY2025 net income $3.2B ($4.71/sh); adjusted EPS ex notable items $8.89, up 10% YoY.
MetLife closes PineBridge acquisition; combined AUM reaches $734.7B
Closed acquisition of PineBridge Investments on December 30, 2025, announced in December 2024.
Q4 2025 variable investment income estimated $385M–$435M pre-tax vs $425M target; FY 2025 private equity return ~7.7%.
MetLife completes $10B variable annuity risk transfer with Talcott Resolution
Transaction reinsures ~$10B of U.S. retail variable annuity and rider reserves with Talcott Resolution.
MetLife Q3 adj EPS $2.34 (+21% YoY); secured $12B PRT mandates in Q4-to-date
Adjusted earnings $1.6B ($2.37/diluted share); adjusted EPS ex-notable items $2.34 (+21% YoY).
MetLife Q2 adjusted EPS $2.02, down 11% YoY; net income $698M; PFOs ex-PRT up 5%
Adjusted earnings $1.36B ($2.02 EPS) vs $1.63B ($2.28) in 2Q24, down 16% (11% per share).
MetLife co-sponsors Chariot Re; transfers ~$10B in annuity liabilities to new reinsurer
Chariot Re, co-sponsored by MetLife and General Atlantic, will reinsure ~$10B of MetLife's structured settlement and pension risk transfer annuity contracts.
MetLife issues ¥87.84B in senior notes across six tranches due 2032-2055
Issued ¥87.84B aggregate principal of yen-denominated senior notes with coupons from 2.14% to 3.62%.
MetLife Q1 net income up 10% to $879M; adjusted EPS $1.96 beats; new $3B buyback
Net income $879M ($1.28/diluted EPS), up 10% YoY; adjusted earnings $1.349B ($1.96/diluted), up 1% YoY.
MetLife to reinsure ~$10B in variable annuity reserves with Talcott; reduces tail risk 40%
Reinsurance agreement with Talcott covers ~$10B of U.S. retail variable annuity and rider reserves.
MetLife FY2024 net income $4.2B, EPS up 228%; raises adjusted ROE target to 15-17%
FY2024 net income of $4.2B ($5.94 EPS) vs $1.4B ($1.81) in 2023; adjusted EPS $8.15, up 12%.
MetLife unveils New Frontier strategy targeting double-digit EPS growth, 15-17% ROE
New five-year strategy aims for double-digit adjusted EPS growth (from ~6%) and 15-17% adjusted ROE (from 12-14%).
MetLife and General Atlantic form Chariot Re; MetLife to cede ~$10B in annuity reserves
MetLife and General Atlantic each take ~15% equity in new Bermuda reinsurer Chariot Re; initial combined equity >$1B; Chubb as anchor third-party investor.
MetLife Q3 adjusted EPS $1.95, down 1% YoY; net income surges to $1.3B on derivative gains
Net income $1.275B ($1.81 per share) vs $422M ($0.56) in Q3'23, up 202% on higher net derivative gains.
MetLife Q2 net income $912M ($1.28 EPS); adj EPS $2.28 beats $1.94; $0.9B buyback in Q2
Net income $912M ($1.28) vs $370M ($0.48) YoY; adjusted earnings $1.628B ($2.28) vs $1.492B ($1.94).
MetLife Q1 net income $800M ($1.10 EPS), adj EPS $1.83; board approves $3B buyback
Net income $800M ($1.10 per share) vs $14M ($0.02) in Q1 2023; adjusted earnings $1.3B ($1.83 per share), up 20% YoY.
On March 27, 2025, David L. Herzog, a director of MetLife, Inc. (the “Company”), notified the Company’s Board of Directors (the “Board”) of his decision to resign from the Board, effective May 1, 2025, and not to stand for re-election at the Company’s 2025 annual meeting of shareholders.
appointed Toby Srihiran Brown, Executive Vice President and Global Head of Reinsurance of the Company, as the Company’s interim Chief Accounting Officer, to be effective as of March 15, 2025
elected Christian Mumenthaler a director of the Company and appointed Mr. Mumenthaler to its Finance and Risk Committee and its Investment Committee, effective May 1, 2025.
Tamara L. Schock, notified the Company of her intent to resign as Executive Vice President and Chief Accounting Officer of the Company.
On January 7, 2025, Tamara L. Schock, Executive Vice President and Chief Accounting Officer of MetLife, Inc. (the “Company”), informed the Company that she would resign from her position to pursue another opportunity.
On February 27, 2024, the Board of Directors (the “Board”) of MetLife, Inc. (the “Company”) elected Laura J. Hay a director of the Company and appointed Ms. Hay to its Audit Committee and its Finance and Risk Committee, effective immediately.
On June 16, 2023, Steven J. Goulart, Executive Vice President and Chief Investment Officer of MetLife, Inc. (the “Company”) and a named executive officer in the Company’s most recent proxy statement, informed the Company that he will retire on August 31, 2023.
On February 28, 2023, the Board of Directors (the “Board”) of MetLife, Inc. (the “Company”) increased the number of directors serving on the Board from thirteen to fourteen and elected Jeh C. Johnson a director of the Company and appointed Mr. Johnson to its Audit Committee and its Governance and Corporate Responsibility Committee, effective immediately.
On April 4, 2022, the Board of Directors (the “Board”) of MetLife, Inc. (the “Company”) increased the number of directors serving on the Board from twelve to thirteen and elected Carla Harris a director of the Company, effective April 27, 2022.
Max materiality 0.90 · Median 0.53 · Most common event other_material